Page 97 - Quest Diagnostics News Today

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 3,230,000 shares, a growth of 6.6% from the July 15th total of 3,030,000 shares. Based on an average daily trading volume, of 893,400 […]

As per the report by Fortune Business Insights, The global C-reactive protein testing market size was valued at USD 2.16 billion in 2022 and is expected to be worth USD 2.29 billion in 2023. The market is projected to reach USD 3.29 billion by 2030, recording a CAGR of 5.3% during the forecast period.Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- The global C-reactive protein testing market size was valued at USD 2.16 billion in 2022 and is expected to be worth USD 2.29 billion in 2023. The mark

As per the report by Fortune Business Insights, The global C-reactive protein testing market size was valued at USD 2.16 billion in 2022 and is expected to...

More CFOs made moves in the first half of 2023, compared to the same period in 2022. 

A blood-based biomarker test that assesses beta amyloid protein has been made available by Quest Diagnostics to help individuals identify their risk of developing Alzheimer disease.

According to a new report from the Maryland Tech Council and other state agencies, life sciences jobs in the state have boomed over the past four years.

Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Lyme disease diagnostics market is expected to total US$ 1.56 billion in 2023 and is expected to

Rise in incidence of the Lyme disease and growth in awareness about diagnostic tests are key Lyme disease diagnostics market drivers. The number of people affected with the Lyme disease is rising, particularly in regions with high prevalence of ticks.Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Lyme disease diagnostics market is expected to total US$ 1.56 billion in 2023 and is expected to expand at a CAGR of 3.8% until 203

Rise in the prevalence of senile dementia associated with Alzheimer's disease due to rapidly aging population is driving the global Alzheimer's disease biomarkers industry. Introduction of specific biomarkers, such as peptides and genes, for diagnosis of Alzheimer's disease is likely to be major business catalyst.Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Alzheimer’s disease biomarkers market is expe...

SAN DIEGO, Aug. 14, 2023 -- Bionano Genomics, Inc.  today announced that Gülsen Kama will serve as its next Chief Financial Officer , effective September 11, 2023. Christopher Stewart, who held... -Today at 08:01 am- MarketScreener